Zimmer Biomet Reshapes U.S. Sales Model As ROSA Knee Gains Ground

Simply Wall St.

Feb 13

Zimmer Biomet Holdings (NYSE:ZBH) has launched a major reorganization of its U.S. salesforce, targeting a fully dedicated and specialized structure by 2027. The company has also secured U.S. FDA ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611132121"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611132121\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611132121?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-02-13 16:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611132121","market":"nz","top_or_hot":-1,"title":"Zimmer Biomet Reshapes U.S. Sales Model As ROSA Knee Gains Ground","media":"Simply Wall St.","content":"<div>\n<p>Zimmer Biomet Holdings (NYSE:ZBH) has launched a major reorganization of its U.S. salesforce, targeting a fully dedicated and specialized structure by 2027. The company has also secured U.S. FDA ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-reshapes-us-sales-model-as-rosa-knee-gains-gro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zimmer Biomet Reshapes U.S. Sales Model As ROSA Knee Gains Ground</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZimmer Biomet Reshapes U.S. Sales Model As ROSA Knee Gains Ground\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-13 16:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-reshapes-us-sales-model-as-rosa-knee-gains-gro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zimmer Biomet Holdings (NYSE:ZBH) has launched a major reorganization of its U.S. salesforce, targeting a fully dedicated and specialized structure by 2027. The company has also secured U.S. FDA ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-reshapes-us-sales-model-as-rosa-knee-gains-gro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBH","symbol_name":"齐默巴奥米特控股","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-reshapes-us-sales-model-as-rosa-knee-gains-gro","article_id":"2611132121","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-reshapes-us-sales-model-as-rosa-knee-gains-gro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611132121","pubTimestamp":1770971719,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Zimmer Biomet Holdings (NYSE:ZBH) has launched a major reorganization of its U.S. salesforce, targeting a fully dedicated and specialized structure by 2027.\nThe company has also secured U.S. FDA clearance for an upgrade to its ROSA robotic-assisted knee system, expanding its capabilities in robotic knee procedures.\nThese moves come as Zimmer Biomet seeks to reshape its commercial model and product offering beyond routine quarterly results or share repurchases.\n\nZimmer Biomet enters this...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ZBH":"齐默巴奥米特控股"},"translate_title":"随着ROSA Knee的普及，Zimmer Biomet重塑美国销售模式","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":1.5},"content_text":"Zimmer Biomet Holdings (NYSE:ZBH) has launched a major reorganization of its U.S. salesforce, targeting a fully dedicated and specialized structure by 2027. The company has also secured U.S. FDA clearance for an upgrade to its ROSA robotic-assisted knee system, expanding its capabilities in robotic knee procedures. These moves come as Zimmer Biomet seeks to reshape its commercial model and product offering beyond routine quarterly results or share repurchases.  Zimmer Biomet enters this transition with its shares at $95.18 and a mixed return profile, including a 7.3% gain over the past week and 7.7% over the past month, alongside a 1 year decline of 3.8%. Over a 3 year period, the stock shows a 21.9% decline, and over 5 years it shows a 34.8% decline. This provides important context as you consider how meaningful these business changes could be for NYSE:ZBH. For investors, the combination of a revamped U.S. sales model and an upgraded ROSA knee platform may indicate how Zimmer Biomet is trying to compete in orthopedic devices over the coming years. Key questions include how temporary any sales disruption proves to be and how effectively the company converts its new structure and regulatory progress into surgeon adoption and procedure volumes. Stay updated on the most important news stories for Zimmer Biomet Holdings by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Zimmer Biomet Holdings. NYSE:ZBH Earnings & Revenue Growth as at Feb 2026 📰 Beyond the headline: 2 risks and 3 things going right for Zimmer Biomet Holdings that every investor should see. Zimmer Biomet’s U.S. salesforce overhaul and the FDA-cleared upgrade to its ROSA knee system sit at the intersection of product adoption and commercial execution. Management has already signalled that moving to a fully dedicated, specialized U.S. sales model could create some short term disruption, and that is reflected in the more measured 2026 guidance of 1% to 3% organic constant currency revenue growth and adjusted EPS of US$8.30 to US$8.45. At the same time, Q4 2025 net sales of US$2,243.8 million versus US$2,023.2 million a year earlier show that demand for hip and knee implants and robotic solutions is there if the company can put the right structure around it. For you as an investor, the key question is whether a more focused U.S. salesforce can convert new tools like ROSA Knee with OptimiZe into higher surgeon usage and procedure share, particularly against large orthopedic peers such as Stryker and Johnson & Johnson’s DePuy Synthes. The recently authorized US$1.5b buyback also signals that Zimmer Biomet is choosing to prioritize capital returns while it works through this operational reset. AdvertisementHow This Fits Into The Zimmer Biomet Holdings Narrative  The ROSA upgrade and data enabled solutions align with the narrative’s focus on robotics and digital health as drivers of higher mix, recurring revenue and potentially stronger margins over time. The slower 2026 organic growth outlook and execution risk around the U.S. salesforce transformation challenge the idea of consistently above market share gains if disruption lasts longer than planned. The scale and timing of the U.S. commercial reorganization are not fully captured in the narrative’s long term assumptions, yet could influence how quickly acquisitions like Paragon 28 and Monogram are commercialized.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for Zimmer Biomet Holdings to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Management expects short term disruption from the U.S. salesforce transition, which could affect growth and earnings if execution slips. ⚠️ Competition from other large orthopedic players such as Stryker and DePuy Synthes in robotics and core joint reconstruction may pressure Zimmer Biomet’s market share and pricing. 🎁 The FDA clearance for ROSA Knee with OptimiZe and strong demand for hips and knees give Zimmer Biomet more tools to support procedure volumes and premium product adoption. 🎁 The new US$1.5b share repurchase authorization, on top of more than US$1.2b already deployed, shows an ongoing commitment to returning capital to shareholders while the business is reshaped.  What To Watch Going Forward From here, you may want to watch how quickly Zimmer Biomet executes on its U.S. salesforce transformation and whether quarterly organic growth stays within the 1% to 3% target range during the transition. Adoption trends for ROSA Knee with OptimiZe and other robotic assisted platforms will be important signals of how well the company is competing in computer guided joint replacement against peers. It is also worth tracking how margins and free cash flow respond to the mix of higher sales investments, acquisition integration and ongoing buybacks. Together, these pieces will help you judge whether recent operational moves are strengthening or diluting the longer term story for NYSE:ZBH. To stay up to date on how the latest news impacts the investment narrative for Zimmer Biomet Holdings, head to the\ncommunity page for Zimmer Biomet Holdings to follow the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zimmer Biomet Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}